Maticic Mojca, Videcnik Zorman Jerneja, Gregorcic Sergeja, Schatz Eberhard, Lazarus Jeffrey V
BMC Infect Dis. 2014;14 Suppl 6(Suppl 6):S14. doi: 10.1186/1471-2334-14-S6-S14. Epub 2014 Sep 19.
Hepatitis C virus (HCV) infection represents a major global health problem, which in high-income countries now mostly affects people who inject drugs (PWID). Many studies show that the treatment of HCV infection is as successful among PWID as among other populations and recently PWID have been included in the international guidelines for the treatment of HCV infection. The aim of this survey was to collect data from European countries on the existence of national strategies, action plans and clinical guidelines for HCV treatment in the general population and PWID in particular.
Thirty-three European countries were invited to participate. Data on available national strategies, action plans and guidelines for HCV treatment in general population and in PWID specifically were collected prospectively by means of a structured electronic questionnaire and analyzed accordingly.
All of the 33 invited European countries participated in the survey. Twenty-two responses came from non-governmental organizations, six from public health institutions, four from university institutions and one was an independent consultant. Fourteen (42.4%) of the countries reported having a national strategy and/or national action plan for HCV treatment, from which ten of them also reported having a national strategy and/or national action plan for treatment of HCV infection in PWID. Nearly three-quarters reported having national HCV treatment guidelines. PWID were included in the majority (66.7%) of the guidelines. Fourteen (42.4%) countries reported having separate guidelines for the treatment of HCV infection in PWID.
Given the high burden of HCV-related morbidity and mortality in PWID in Europe, the management of HCV infection should become a healthcare priority in all European countries, starting with developing or using already-existing national strategies, action plans and guidelines for this population.
丙型肝炎病毒(HCV)感染是一个重大的全球健康问题,在高收入国家,目前主要影响注射毒品者(PWID)。许多研究表明,HCV感染在PWID中的治疗效果与在其他人群中一样好,并且最近PWID已被纳入HCV感染的国际治疗指南。本次调查的目的是收集欧洲国家关于普通人群尤其是PWID中HCV治疗的国家战略、行动计划和临床指南的存在情况的数据。
邀请了33个欧洲国家参与。通过结构化电子问卷前瞻性收集关于普通人群以及特定PWID中可用的HCV治疗国家战略、行动计划和指南的数据,并进行相应分析。
所有33个受邀欧洲国家都参与了调查。22份回复来自非政府组织,6份来自公共卫生机构,4份来自大学机构,1份来自独立顾问。14个(42.4%)国家报告有HCV治疗的国家战略和/或国家行动计划,其中10个国家还报告有针对PWID中HCV感染治疗的国家战略和/或国家行动计划。近四分之三的国家报告有国家HCV治疗指南。大多数指南(66.7%)将PWID纳入其中。14个(42.4%)国家报告有针对PWID中HCV感染治疗的单独指南。
鉴于欧洲PWID中与HCV相关的发病率和死亡率负担较高,HCV感染的管理应成为所有欧洲国家的医疗保健优先事项,首先是为该人群制定或使用现有的国家战略、行动计划和指南。